tradingkey.logo
tradingkey.logo
Search

Eli Lilly and Co

LLY
Add to Watchlist
1185.665USD
+22.655+1.95%
Close 07-23 16:00ETQuotes delayed by 15 min
1.12TMarket Cap
42.04P/E TTM

Eli Lilly and Co

1185.665
+22.655+1.95%
View Detailed Chart
TradingKey Chart
Intraday
1m
30m
1h
D
W
M
D

Today

+1.95%

5 Days

+1.41%

1 Month

+7.10%

6 Months

+11.40%

Year to Date

+10.33%

1 Year

+48.41%

Key Figures
1147.660Open
1189.590High
1.91MVolume
42.04P/E TTM
27.78P/E Dynamic
6.230Dividend TTM
0.20%Turnover Ratio
1163.010Prev. Close
1142.010Low
1.12BTurnover
105.64P/E Static
35.86P/B
0.53%Div Yield TTM
24.54%ROA
1149.10052wk High
0.81Volume Ratio
10.59BNet Profit
943.50MShares
28.2003EPS TTM
0.53Beta
107.65%ROE
623.78052wk Low
4.09%Amplitude
81.93%Gross Margin
1.12TMarket Cap
2.27Reward/Risk
1.80%Risk Rate

TradingKey Stock Score of Eli Lilly and Co

Currency: USD Updated: 2026-07-23

Key Insights

Eli Lilly and Co's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 12 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 1245.37.In the medium term, the stock price is expected to trend up.Despite a good stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Eli Lilly and Co's Score

Industry at a Glance

Industry Ranking
12 / 155
Overall Ranking
44 / 4547
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

49°C

Very Low
Very High
Neutral

Eli Lilly and Co Highlights

StrengthsRisks

Eli Lilly and Company, commonly referred to as Lilly, is an American multinational pharmaceutical corporation based in Indianapolis, Indiana, with offices in 18 countries and products available in approximately 125 nations. Founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran from the American Civil War, the company carries his name.

As of October 2024, Lilly has achieved the status of the most valuable drug company in the world, boasting a market capitalization of $842 billion, marking the highest valuation ever recorded for a pharmaceutical company. The firm ranks 127th on the Fortune 500, reporting revenues of $34.12 billion. Additionally, it is positioned 221st on the Forbes Global 2000 list, which encompasses the largest publicly traded companies globally, and 252nd on Forbes' list of "America's Best Employers."

Lilly is recognized for its antidepressant medications, including Prozac and Cymbalta, as well as the antipsychotic drug Zyprexa. Its primary revenue sources are the diabetes treatments Humalog and Trulicity.

The company was a pioneer in mass-producing both the polio vaccine, created in 1955 by Jonas Salk, and insulin. Lilly was among the first in the pharmaceutical sector to manufacture human insulin using recombinant DNA technology, producing products like Humulin, Humalog, and the first approved biosimilar insulin in the U.S., known as Basaglar. Additionally, Lilly introduced exenatide to the market as the first of the GLP-1 receptor agonists, followed by highly successful medications in this category, such as Mounjaro and Zepbound.

By 1997, Lilly had become both the largest corporation and the largest philanthropic benefactor in Indiana. In 2009, it pleaded guilty to illegally marketing Zyprexa and agreed to a substantial $1.415 billion settlement, which included a criminal fine of $515 million, making it the largest ever in a healthcare-related case and the highest criminal fine levied against a single corporation in a U.S. criminal prosecution at that time.

Lilly is a full member of the Pharmaceutical Research and Manufacturers of America, as well as the European Federation of Pharmaceutical Industries and Associations.

High Growth
The company's revenue has grown steadily over the past 3 years, averaging 91.01% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 65.18B.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 45.87%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 45.87%.
Undervalued
The company’s latest PE is 42.05, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 864.16M shares, increasing 7.39% quarter-over-quarter.
Held by Bernard Horn
Star Investor Bernard Horn holds 775.44K shares of this stock.

Analyst Rating

Based on 34 analysts
Buy
Current Rating
1245.374
Target Price
+5.95%
Upside Space

Eli Lilly and Co News

Novo Nordisk Sues Eli Lilly for False Advertising: Weight-Loss Drug Data War Escalates, GLP-1 $100 Billion Market Fight Heats Up

TradingKey - Novo Nordisk (NVO) has officially filed a lawsuit in the U.S. District Court for the District of New Jersey, alleging that Eli Lilly’s (LLY) advertisements for its blockbuster weight-loss drug Zepbound and diabetes injection Mounjaro are misleading and violate federal and state laws concerning false advertising and unfair competition. The essence of the lawsuit is a data war between the two pharmaceutical giants over the multi-hundred-billion-dollar GLP-1 drug market, where the key weapon on the battlefield is a set of clinical comparison data alleged to be "outdated."

TradingKeyTue, Jul 21
TradingKey - Novo Nordisk (NVO) has officially filed a lawsuit in the U.S. District Court for the District of New Jersey, alleging that Eli Lilly’s (LLY) advertisements for its blockbuster weight-loss drug Zepbound and diabetes injection Mounjaro are misleading and violate federal and state laws concerning false advertising and unfair competition. The essence of the lawsuit is a data war between the two pharmaceutical giants over the multi-hundred-billion-dollar GLP-1 drug market, where the key weapon on the battlefield is a set of clinical comparison data alleged to be "outdated."

US Pre-Market: Chip Stocks Rebound Leads Nasdaq Futures, Marvell Surges Nearly 9% Pre-Market to Be Added to S&P 500

TradingKey - On Monday Eastern Time, all three major U.S. stock index futures rose in pre-market trading as technology stocks recovered from last week's sell-off, with a rebound in chip stocks leading gains in Nasdaq futures. However, escalating tensions in the Middle East pushed oil prices higher, and market concerns regarding inflationary pressures and the Federal Reserve's policy path persist. As of press time, Dow futures rose 0.36%, S&P 500 futures rose 0.83%, and Nasdaq futures rose 1.49%.

TradingKeyMon, Jun 8
TradingKey - On Monday Eastern Time, all three major U.S. stock index futures rose in pre-market trading as technology stocks recovered from last week's sell-off, with a rebound in chip stocks leading gains in Nasdaq futures. However, escalating tensions in the Middle East pushed oil prices higher, and market concerns regarding inflationary pressures and the Federal Reserve's policy path persist. As of press time, Dow futures rose 0.36%, S&P 500 futures rose 0.83%, and Nasdaq futures rose 1.49%.

Eli Lilly Zepbound Returns to CVS Formulary, Pre-Market Shares Rise as Much as 2%

TradingKey - Eli Lilly (LLY) shares rose nearly 2% in Thursday’s pre-market session as the market focused on a major decision from U.S. healthcare giant CVS Health (CVS). CVS announced it would restore insurance coverage for the weight-loss drug Zepbound and include Foundayo, an oral weight-loss medication newly approved in April, in its standard drug formulary.

TradingKeyThu, May 28
TradingKey - Eli Lilly (LLY) shares rose nearly 2% in Thursday’s pre-market session as the market focused on a major decision from U.S. healthcare giant CVS Health (CVS). CVS announced it would restore insurance coverage for the weight-loss drug Zepbound and include Foundayo, an oral weight-loss medication newly approved in April, in its standard drug formulary.

Eli Lilly Bets Nearly $4 Billion on Vaccines: Is the Weight-Loss Drug Giant’s Next Growth Curve Here?

TradingKey - On May 26, Eli Lilly (LLY) announced the acquisition of three vaccine R&D companies—Curevo, LimmaTech Biologics, and Vaccine Company—for a total transaction value of up to nearly $4 billion. Specifically, Eli Lilly will pay up to $1.5 billion in cash for Curevo, up to $780 million for LimmaTech, and up to $1.55 billion for Vaccine Company.

TradingKeyTue, May 26
TradingKey - On May 26, Eli Lilly (LLY) announced the acquisition of three vaccine R&D companies—Curevo, LimmaTech Biologics, and Vaccine Company—for a total transaction value of up to nearly $4 billion. Specifically, Eli Lilly will pay up to $1.5 billion in cash for Curevo, up to $780 million for LimmaTech, and up to $1.55 billion for Vaccine Company.

Today’s Market Recap:Optimism over US-Iran Talks Drives US Stock Futures Higher, Crude Oil Plunges 6%

TradingKey - Stock futures jumped on Monday night as oil prices slid and hope grew that a resolution to the U.S.-Iran war was within reach.

TradingKeyTue, May 26
TradingKey - Stock futures jumped on Monday night as oil prices slid and hope grew that a resolution to the U.S.-Iran war was within reach.

Eli Lilly Weight-Loss Drug Retatrutide Posts Impressive Data; Can Novo Nordisk Break Through After Falling Behind Again?

TradingKey - On May 21, Eastern Time, Eli Lilly announced the results of the pivotal Phase 3 clinical trial (TRIUMPH-1) for its next-generation weight-loss drug, Retatrutide. As the world's first "triple agonist" targeting GIP, GLP-1, and glucagon receptors, its efficacy data has comprehensively sur

TradingKeyMon, May 25
TradingKey - On May 21, Eastern Time, Eli Lilly announced the results of the pivotal Phase 3 clinical trial (TRIUMPH-1) for its next-generation weight-loss drug, Retatrutide. As the world's first "triple agonist" targeting GIP, GLP-1, and glucagon receptors, its efficacy data has comprehensively sur

Earnings Forecast

Analyst Rating

Based on 34 analysts
Buy
Current Rating
1245.374
Target Price
+5.95%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Eli Lilly and Co
LLY
34
Biogen Inc
BIIB
38
Amgen Inc
AMGN
37
AbbVie Inc
ABBV
33
Merck & Co Inc
MRK
32
Pfizer Inc
PFE
32
1
2
3
...
32

Indicators

Indicators
Sell(2)
Neutral(3)
Buy(2)
Indicators
Value
Direction
MACD(12,26,9)
-13.487
Neutral
RSI(14)
55.213
Neutral
STOCH(KDJ)(9,3,3)
58.786
Buy
ATR(14)
37.113
High Vlolatility
CCI(14)
-29.116
Neutral
Williams %R
55.263
Sell
TRIX(12,20)
0.151
Sell
StochRSI(14)
100.000
Buy
Moving Average
Sell(1)
Neutral(0)
Buy(5)
Indicators
Value
Direction
MA5
1170.060
Buy
MA10
1169.909
Buy
MA20
1186.916
Sell
MA50
1125.297
Buy
MA100
1032.688
Buy
MA200
1014.367
Buy

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Eli Lilly and Co Info

Eli Lilly and Company, commonly referred to as Lilly, is an American multinational pharmaceutical corporation based in Indianapolis, Indiana, with offices in 18 countries and products available in approximately 125 nations. Founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran from the American Civil War, the company carries his name.

As of October 2024, Lilly has achieved the status of the most valuable drug company in the world, boasting a market capitalization of $842 billion, marking the highest valuation ever recorded for a pharmaceutical company. The firm ranks 127th on the Fortune 500, reporting revenues of $34.12 billion. Additionally, it is positioned 221st on the Forbes Global 2000 list, which encompasses the largest publicly traded companies globally, and 252nd on Forbes' list of "America's Best Employers."

Lilly is recognized for its antidepressant medications, including Prozac and Cymbalta, as well as the antipsychotic drug Zyprexa. Its primary revenue sources are the diabetes treatments Humalog and Trulicity.

The company was a pioneer in mass-producing both the polio vaccine, created in 1955 by Jonas Salk, and insulin. Lilly was among the first in the pharmaceutical sector to manufacture human insulin using recombinant DNA technology, producing products like Humulin, Humalog, and the first approved biosimilar insulin in the U.S., known as Basaglar. Additionally, Lilly introduced exenatide to the market as the first of the GLP-1 receptor agonists, followed by highly successful medications in this category, such as Mounjaro and Zepbound.

By 1997, Lilly had become both the largest corporation and the largest philanthropic benefactor in Indiana. In 2009, it pleaded guilty to illegally marketing Zyprexa and agreed to a substantial $1.415 billion settlement, which included a criminal fine of $515 million, making it the largest ever in a healthcare-related case and the highest criminal fine levied against a single corporation in a U.S. criminal prosecution at that time.

Lilly is a full member of the Pharmaceutical Research and Manufacturers of America, as well as the European Federation of Pharmaceutical Industries and Associations.

Ticker SymbolLLY
CompanyEli Lilly and Co
CEORicks (David A)
Websitehttps://www.lilly.com/

Shareholders

Shareholders
Shareholders
Proportion
Lilly Endowment, Inc.
9.76%
Vanguard Capital Management, LLC
5.67%
PNC Investments LLC
5.43%
BlackRock Institutional Trust Company, N.A.
4.44%
State Street Investment Management (US)
3.75%
Other
70.95%

FAQs

What is the current price of Eli Lilly and Co (LLY)?

The current price of Eli Lilly and Co (LLY) is 1185.66.

What is the symbol of Eli Lilly and Co?

The ticker symbol of Eli Lilly and Co is LLY.

What is the 52-week high of Eli Lilly and Co?

The 52-week high of Eli Lilly and Co is 1149.10.

What is the 52-week low of Eli Lilly and Co?

The 52-week low of Eli Lilly and Co is 623.78.

What is the market capitalization of Eli Lilly and Co?

The market capitalization of Eli Lilly and Co is 1.12T.

Is Eli Lilly and Co (LLY) currently rated as Buy, Hold, or Sell?

According to analysts, Eli Lilly and Co (LLY) has an overall rating of Buy, with a price target of 1245.37.

What is the Earnings Per Share (EPS TTM) of Eli Lilly and Co (LLY)?

The Earnings Per Share (EPS TTM) of Eli Lilly and Co (LLY) is 23.00.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.